ERBB2 and Hodgkins lymphoma: FDA approved recently two products, the CD30-targeting ADC brentuximab-vedotin for the treatment of relapsed Hodgkin lymphoma and of anaplastic large cell lymphoma [17], and ado-trastuzumab emtansine (T-DM1) for the treatment of HER2/neu-positive metastatic endometrial cancer [18].